Epsilogen licenses first-in-class IgE ovarian cancer drug

UK biotech Epsilogen has licensed rights to a drug for solid tumours developed by Kings College London and Cancer Research UK that it says is the first immunoglobulin E (IgE) drug to start clinical trials.